IgA肾病的研究进展  

Research Progress of IgA Nephropathy

作　　者：庄文芳[1] 吴红赤[1] 

机构地区：[1]哈尔滨医科大学附属第一医院肾内科,哈尔滨150001

出　　处：《医学综述》2017年第14期2785-2789,共5页Medical Recapitulate

摘　　要：Ig A肾病是全球最常见的原发性肾小球肾炎,是年轻肾脏疾病患者的重要病因,同时也是引起终末期肾衰竭的主要原因之一。该病呈进行性发展,预后较差。目前,Ig A肾病发病机制尚未完全明确,仍缺乏行之有效的治疗方法,其治疗原则主要是控制血压、蛋白尿及保护肾功能。Ig A肾病的临床过程变异很大,从完全良性到发展至终末期肾衰竭,预后较难预测。而关于其治疗,包括治疗适应证、时机、方案(免疫抑制剂治疗、靶向治疗)等未来仍有待研究。IgA nephropathy is the most common primary glomerular nephritis in the world. It is an important cause of renal disease in young patients and one of the main causes of end-stage renal failure. The disease is progressive and has a poor prognosis. At present, the pathogenesis of IgA nephropathy is not fully understood, and it still lacks of effective treatment methods. The treatment principle of IgA nephropathy is to control blood pressure, albuminuria and protect renal function. The clinical course from the complete benign process to the end-stage renal failure of immunoglobulin A nephropathy varies greatly, and the prognosis is difficult to predict. The treatment of immunoglobulin A nephropathy, including treatment indications, timing, regimens（ such as immunosuppressive therapy ,targeted therapy）, still need to be explored.

关 键 词：IGA肾病 肾小球肾炎 免疫抑制剂 

分 类 号：R692[医药卫生—泌尿科学]